3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
8
Head & Neck
4
Genitourinary
4
Gastrointestinal
4
Dermatologic
4
Thoracic
3
Breast
3
Other solid neoplasm
1
Lymphoid
1
Conditions
Mesothelioma, Malignant
5
Unspecified Adult Solid Tumor, Protocol Specific
3
Solid Tumor, Adult
3
Solid Tumor
2
Pleural Effusion, Malignant
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Skin Neoplasms
1
Select Advanced Solid Tumors
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Advanced Solid Tumors
1
Advanced Refractory Solid Tumors
1
Advanced Malignant Solid Tumor
1
Interventions
pembrolizumab
8
Nivolumab
3
tislelizumab
2
spartalizumab
2
SS1(dsFv)PE38
2
Ipilimumab
2
fludarabine phosphate
1
fludarabine
1
epacadostat
1
entinostat
1
bosutinib
1
atezolizumab
1
aldesleukin
1
Quality of Life
1
Polymerase Chain Reaction
1
Platinum
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Molecular Diagnostic Techniques
1
Microarray Analysis
1
Interleukin-2
1
Immunotherapy
1
Immunoenzyme Techniques
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gene Expression Profiling
1
Gemcitabine
1
Flow Cytometry
1
Fentanyl
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Interleukin-2
×
Other solid neoplasm
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled